ArticleBMC women's health2025
Analysis of clinicopathological features and clinical significance in 25 cases of mammary adenoid cystic carcinoma.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Basaloid-Solid Adenoid Cystic Carcinoma of the Breast: A Case Report and Literature Review.Case reports in pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMammary adenoid cystic carcinoma (AdCC) is a rare subtype of invasive breast cancer. Due to its low incidence, the clinicopathological features of mammary AdCC remain incompletely understood. This study aimed to investigate the clinicopathological and molecular characteristics, therapeutic regimens, and prognostic outcomes associated with different subtypes of mammary AdCC.
methodsA total of 25 archived specimens of mammary AdCC were collected from the pathology departments of Nanchang People's Hospital and Zhengzhou People's Hospital between January 2013 and December 2024. Histomorphological evaluation, immunohistochemical (IHC) analysis, and molecular testing were performed to evaluate the clinicopathological features and prognostic outcomes. Fisher's exact test was used to analyze the relationship between HER2 status and clinicopathological features.
resultsAll 25 patients were female, with a mean age of 57.04 years. The tumors manifested as solitary solid nodules, ranging in maximum diameter from 1 to 4.5 cm. Histologically, the tumors were classified as classic adenoid cystic carcinoma (C-AdCC) (21/25), solid-basaloid AdCC (SB-AdCC) (2/25) and AdCC with high-grade transformation (2/25), with Nottingham grade II being the most common (18/25). Immunohistochemical (IHC) analysis demonstrated that most cases exhibited a triple-negative phenotype, characterized by ER-negative (21/25), PR-negative (25/25), and HER2 negativity (IHC score of 0, 1+, or 2 + with no amplification detected by FISH) (25/25). HER2-low expression (IHC score of 1+/2 + with FISH-confirmed non-amplification) was observed in 11 cases (11/25). Neuroendocrine markers were negative in all cases. MYB gene abnormalities, including break-parts or fusion, were identified in 14/25 cases. A statistically significant positive correlation (P < 0.05) was observed between HER2-low expression and MYB gene abnormalities. Axillary lymph node metastasis was observed in 2/25 patients. Following treatment, which included various surgical modalities with or without neoadjuvant chemotherapy, and a follow-up period of 6-136 months, 21 patients remained alive without recurrence or metastasis, 1 patient died at 60 months, and 3 patients were lost to follow-up.
conclusionsThese findings support the classification of mammary AdCC as a distinct triple-negative breast cancer (TNBC), with MYB gene abnormalities showing a positive correlation with HER2 status. Notably, mammary AdCC should not be indiscriminately categorized as low-grade TNBC. Precise pathological subtyping of AdCC is critical for guiding clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.